Transdermal ketamine - Silo Pharma/Zylo Therapeutics
Alternative Names: SP-26Latest Information Update: 24 Jul 2024
At a glance
- Originator Silo Pharma; Zylo Therapeutics
- Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Mood stabilisers; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
- Mechanism of Action AMPA receptor agonists; Dopamine receptor agonists; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Fibromyalgia; Pain
Most Recent Events
- 24 Jul 2024 Preclinical trials in Pain in USA (Transdermal) before July 2024 (Silo Pharma pipeline, July 2024)